Related Experiment Video
Updated: Mar 26, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
[Clinicopathological features and survival of bone metastasis from primary hepatic carcinoma]
Yongfei Guo1, Zhi Guo2, Haipeng Yu1
1Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin 300060, China.
Objective:
To explore clinicopathological features and prognostic factors of bone metastasis from primary hepatic carcinoma (PHC).
Methods:
Eighty patients were enrolled with bone metastasis from PHC in Tianjin Medical University Cancer Institute and Hospital from January 2005 to June 2014 respectively. The clinicopathological features and prognostic factors of primary tumor were collected and bone metastases. Kaplan-Meier method was adopted for survival analysis. Log-rank method and Cox regression were used for univariate and multivariate analysis.
Results:
The median survival was 4.7 (95% CI range from 3.4 to 6.0) months. The 6-, 12-, and 24-month survival was 42.5%, 17.5%, 2.5%, respectively. Univariate analysis indicated that Child-Pugh grading (P<0.01), ECOG score (P=0.014), serum cholinesterase (P=0.002), total bilirubin (P=0.006), ascites (P=0.003), TACE (P<0.01) were significant prognostic factors of survival. Multivariate analysis revealed that Child-Pugh classification (P<0.01), TACE (P<0.01) were independent prognostic factors of survival.
Conclusion:
Bone metastasis from PHC patients had poor survival. Patients can benefit from TACE and liver protecting treatment.
